Company / Working Capital
Rein Therapeutics, Inc. Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$1.9M
FY2025
5-year range
-$1.9M / $43.7M
FY2021-FY2025
Trend
-123.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $44M in FY2021 to -$2M in FY2025.
Based on SEC 10-K filings.
-$2M in FY2025.
Declined from $14M to -$2M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Rein Therapeutics, Inc.'s working capital has declined for 4 consecutive years.
- In FY2025, working capital decreased 123.4% year-over-year.
- Peak working capital was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.9M | -123.4% |
| FY2024 | $7.9M | -43.0% |
| FY2023 | $13.9M | -24.9% |
| FY2022 | $18.5M | -57.7% |
| FY2021 | $43.7M | +253.1% |
| FY2020 | $12.4M | -9.8% |
| FY2019 | $13.7M | -16.4% |
| FY2018 | $16.4M | -65.1% |
| FY2017 | $46.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026